SAFETY DATA SHEETS

This SDS packet was issued with item:

078950656

N/A



SAFETY DATA SHEET

SECTION 1: IDENTIFICATION

Product Name: Lactated Ringer's Injection, USP

Manufacturer Name: Fresenius Kabi USA, LLC Three Corporate Drive Address:

Lake Zurich, Illinois 60047 (847) 550-2300

General Phone Number:

Customer Service Phone

(888) 386-1300

(800) 551-7176 Health Issues Information: SDS Creation Date: February 14, 2019 SDS Revision Date: February 14, 2019

SECTION 2: HAZARD(S) IDENTIFICATION

Signal Word: Not a hazardous substance or mixture.

GHS Class: Not a hazardous substance or mixture. Hazard Statements: Not a hazardous substance or mixture. Precautionary Statements: Not a hazardous substance or mixture.

Emergency Overview: This product is intended for therapeutic use only when prescribed by a physician. Potential adverse

reactions from prescribed doses and overdoses are described in the package insert.

Route of Exposure: Inhalation Ingestion Eye contact Skin Absorption. Injection.

Potential Health Effects:

Eye: Contact with eyes may cause irritation.

Skin: May cause skin irritation.

Inhalation: May cause irritation of respiratory tract.

Ingestion: May cause irritation.

Aggravation of Pre-Existing

Conditions:

Individuals with hypernatremia or fluid retention.

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

Chemical Name	CAS#	Ingredient Percent	EC Num.
Potassium chloride	7447-40-7	0.3 mg/mL by weight	231-211-8
Sodium lactate	72-17-3	3.1 mg/mL by weight	200-772-0
Calcium chloride	10043-52-4	0.2 mg/mL by weight	233-140-8
Sodium Chloride	7647-14-5	6 mg/mL by weight	231-598-3
Water for Injection	7732-18-5	quantity sufficient	

SECTION 4: FIRST AID MEASURES

Eye Contact: Immediately flush eyes with plenty of water for at least 15 to 20 minutes. Ensure adequate flushing of the eyes by separating the eyelids with fingers. Get immediate medical attention.

Immediately wash skin with plenty of soap and water for 15 to 20 minutes, while removing contaminated clothing and shoes. Get medical attention if irritation develops or persists. Skin Contact:

Inhalation: If inhaled, remove to fresh air. If not breathing, give artificial respiration or give oxygen by trained

personnel. Seek immediate medical attention.

If conscious, flush mouth out with water immediately. Call a physician or poison control center immediately. Do not induce vomiting unless directed to do so by medical personnel. Never give Ingestion:

anything by mouth to an unconscious person.

Other First Aid: For Adverse Event Information, please call (800) 551-7176.

SECTION 5: FIRE FIGHTING MEASURES

Flash Point: Not established. Flash Point Method: Not established. Auto Ignition Temperature: Not established. Lower Flammable/Explosive Limit: Not established. Upper Flammable/Explosive Limit: Not established.

Fire Fighting Instructions: Evacuate area of unprotected personnel. Use cold water spray to cool fire exposed containers to

minimize risk of rupture. Do not enter confined fire space without full protective gear. If possible,

contain fire run-off water.

Extinguishing Media: Use alcohol resistant foam, carbon dioxide, dry chemical, or water fog or spray when fighting fires

involving this material.

Use extinguishing measures that are appropriate to local circumstances and the surrounding

environment.

As in any fire, wear Self-Contained Breathing Apparatus (SCBA), MSHA/NIOSH (approved or equivalent) Protective Equipment:

and full protective gear.

Hazardous Combustion

Byproducts:

Thermal decomposition products may include smoke and toxic fumes. Oxides of carbon, oxides of nitrogen and other organic substances may be formed. Other undetermined low molecular weight hydrocarbon compounds may be released in small quantities depending upon specific conditions of

combustion.

SECTION 6: ACCIDENTAL RELEASE MEASURES

Personal Precautions: Evacuate area and keep unnecessary and unprotected personnel from entering the spill area.

Avoid personal contact and breathing vapors or mists. Use proper personal protective equipment as

Environmental Precautions: Avoid runoff into storm sewers, ditches, and waterways.

Contain spills with an inert absorbent material such as soil, sand or oil dry. Methods for containment:

Absorb spill with inert material (e.g., dry sand or earth), then place in a chemical waste container. After Methods for cleanup:

removal, flush spill area with soap and water to remove trace residue

SECTION 7: HANDLING and STORAGE

Handling: When handling pharmaceutical products, avoid all contact and inhalation of vapor, mists and/or fumes.

Use with adequate ventilation. Use only in accordance with directions

Storage: Store at controlled room temperature 20 to 25°C (68 to 77°F). [See USP Controlled Room

Temperature 1. Do not freeze

Work Practices: Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety

Hygiene Practices: Wash thoroughly after handling. Avoid contact with eyes and skin. Avoid inhaling vapor or mist.

SECTION 8: EXPOSURE CONTROLS, PERSONAL PROTECTION

Engineering Controls: General ventilation is sufficient if this product is being used in a controlled medical setting (clinic,

hospital, medical office) for its sole intended parenteral (injection) purpose. Otherwise, use appropriate engineering control such as process enclosures, local exhaust ventilation, or other engineering controls including use of a biosafety cabinet / fume hood to control airborne levels below recommended

exposure limits.

Eye/Face Protection: Chemical splash goggles. Wear a face shield also when splash hazard exist.

Skin Protection Description: Protective laboratory coat, apron, or disposable garment recommended

Hand Protection Description: Wear appropriate protective gloves. Consult glove manufacturer's data for permeability data.

Nitrile rubber or natural rubber gloves are recommended.

Respiratory Protection: No personal respiratory protective equipment is normally required when this product is being used/administered by a licensed healthcare practitioner (i.e. an end-user such as a clinician / doctor /

nurse) for its sole intended parenteral (injection) purpose in a controlled medical setting. The need for respiratory protection will vary according to the airborne concentrations and environmental conditions. A NIOSH approved air-purifying respirator with an organic vapor cartridge or canister may be permissible under certain circumstances. Consult the NIOSH web site

(http://www.cdc.gov/niosh/npptl/topics/respirators/) for a list of respirator types and approved suppliers.

Other Protective: Consult with local procedures for selection, training, inspection and maintenance of the personal

protective equipment.

EXPOSURE GUIDELINES

Potassium chloride:

Guideline ACGIH: TLV-STEL: 2 ppm(ceiling)

Guideline OSHA: OSHA PEL-STEL 5 ppm Ceiling/Peak

SECTION 9: PHYSICAL and CHEMICAL PROPERTIES

Physical State: Liquid solution.

Color: Colorless. Odor: Odorless.

Boiling Point: Not established.

Not established. Melting Point: Solubility: Soluble, in water, Vapor Density: Not established.

Vapor Pressure: Not established. Not established. Percent Volatile:

Molecular Formula: Mixture 58.44 Molecular Weight:

pH:

Flash Point: Not established. Flash Point Method: Not established. Auto Ignition Temperature: Not established.

SECTION 10: STABILITY and REACTIVITY

Chemical Stability: Stable under normal temperatures and pressures.

4.5 - 7.0

Hazardous Polymerization: Not reported.

Conditions to Avoid: Excessive heat may cause decomposition.

SECTION 11: TOXICOLOGICAL INFORMATION

Eye, skin, and respiratory irritation may occur. Acute Toxicity:

Acute Effects: Eye, skin, and respiratory irritation may occur.

Chronic Effects: None known.

Potassium chloride:

RTECS Number: TS8050000

Eye: Eye - Rabbit Total particulate/dust (T): 5 mg/30S (RTECS)

Skin: Administration onto the skin - Human Standard Draize test.: 4 %/24H (RTECS)

Inhalation: Inhalation - Rat LC50: 3124 ppm/1H [Sense Organs and Special Senses (Olfaction) - effect, not

Otherwise specified Sense Organs and Special Senses (Eye) - Iritis]
Inhalation - Mouse LC50: 1108 ppm/1H [Sense Organs and Special Senses (Eye) - effect, not

Otherwise specified Lungs, Thorax, or Respiration - Respiratory stimulation Skin and Appendages - Dermatitis, other (After systemic exposure)]

Inhalation - Rat LC50: 45000 mg/m3/5M [Lungs, Thorax, or Respiration - Acute pulmonary edema]

Inhalation - Rat LC50: 8300 mg/m3/30M [Lungs, Thorax, or Respiration - Acute pulmonary edema] Inhalation - Mouse LC50: 8300 mg/m3/30M [Lungs, Thorax, or Respiration - Acute pulmonary edema] Inhalation - LC50: 0.1 gm/m3 [Details of toxic effects not reported other than lethal dose value] Inhalation - Rat LC50: 60938 mg/m3/5M [Lungs, Thorax, or Respiration - Acute pulmonary edema] Inhalation - Mouse LC50: 20487 mg/m3/5M [Lungs, Thorax, or Respiration - Acute pulmonary edema] Inhalation - Rat LC50: 7004 mg/m3/30M [Lungs, Thorax, or Respiration - Acute pulmonary edema] Inhalation - Mouse LC50: 3940 mg/m3/30M [Lungs, Thorax, or Respiration - Acute pulmonary edema] Inhalation - Rat LC50: 3700 ppm/30M [Details of toxic effects not reported other than lethal dose

Inhalation - Mouse LC50: 2644 ppm/30M [Details of toxic effects not reported other than lethal dose

value] (RTECS)

Ingestion: Oral - Rabbit LD50: 900 mg/kg [Details of toxic effects not reported other than lethal dose value]

(RTECS)

Sodium lactate :

Eye:

Eye - Rabbit Standard Draize test.: 400 ug Eye - Rabbit Standard Draize test.: 50 ug/24H (RTECS)

Skin: Administration onto the skin - Rabbit Standard Draize test.: 500 mg/24H

Ingestion: Oral - Rabbit LDLo: 500 mg/kg [Details of toxic effects not reported other than lethal dose value]

Calcium chloride:

RTECS Number: EV9800000

Sodium Chloride:

Eye - Rabbit Standard Draize test.: 10 mg [Moderate] Eve:

Skin: Administration onto the skin - Rabbit LD50: >10 gm/kg [Details of toxic effects not reported other than

Administration onto the skin - Rabbit Standard Draize test.: 50 mg/24H [mild] Administration onto the skin - Rabbit Standard Draize test.: 500 mg/24H [mild]

Inhalation: Inhalation - Rat LC50: >42 gm/m3/1H [Details of toxic effects not reported other than lethal dose

value]

Oral - Mouse LD50: 4 gm/kg [Details of toxic effects not reported other than lethal dose value] Oral - Rat LD50: 3000 mg/kg [Details of toxic effects not reported other than lethal dose value] Ingestion:

Other Toxicological Information: Intravenous. - Mouse LD50: 645 mg/kg [Details of toxic effects not reported other than lethal dose

Intravenous. - Rabbit LDLo: 1100 mg/kg [Behavioral - convulsions or effect on seizure threshold

Behavioral - muscle contraction or spasticity Cardiac - other changes]

Intravenous. - Guinea pig LDLo: 300 mg/kg [Details of toxic effects not reported other than lethal dose

Intravenous. - Mouse TDLo: 2.1 mg/kg [Vascular - other changes Blood - hemorrhage Skin and Appendages - dermatitis, irritative (after systemic exposure)]

Intravenous. - Rabbit LDLo: 1.5 mg/kg [Details of toxic effects not reported other than lethal dose value]

Intravenous. - Rabbit TDLo: 0.04 mg/kg [Vascular - other changes Blood - hemorrhage Skin and

Appendages - dermatitis, irritative (after systemic exposure)] Subcutaneous - Rat LDLo: 3500 mg/kg [Behavioral - irritability]

Subcutaneous - Mouse LD50: 3 gm/kg [Details of toxic effects not reported other than lethal dose value]

Subcutaneous - Guinea pig LDLo: 2160 mg/kg [Details of toxic effects not reported other than lethal

dose value] Subcutaneous - Rabbit TDLo: 0.04 mg/kg [Vascular - other changes Skin and Appendages - dermatitis,

irritative (after systemic exposure)]

Subcutaneous - Mouse TDLo: 1900 mg/kg [Reproductive - Effects on Embryo or Fetus - fetal death]
Subcutaneous - Mouse TDLo: 1900 mg/kg [Reproductive - Specific Developmental Abnormalities -

musculoskeletal system]

Subcutaneous - Mouse TDLo: 2500 mg/kg [Reproductive - Effects on Embryo or Fetus - fetotoxicity

(except death, e.g., stunted fetus)]

Subcutaneous - Mouse TDLo: 13440 mg/kg [Reproductive - Fertility - abortion]
Intraperitoneal. - Mouse LD50: 2602 mg/kg [Details of toxic effects not reported other than lethal dose

Intraperitoneal. - Rat LD50: 2600 mg/kg [Details of toxic effects not reported other than lethal dose value]

value]
Intraperitoneal. - Rat LDLo: 3.72 gm/kg [Behavioral - tremor Behavioral - convulsions or effect on seizure threshold]
Intraperitoneal. - Rat TDLo: 1710 mg/kg [Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - musculoskeletal system]
Intraperitoneal. - Rat TDLo: 10 gm/kg [Reproductive - Effects on Newborn - behavioral]
Intraperitoneal. - Rat Cytogenetic analysis: 2338 mg/kg

SECTION 12: ECOLOGICAL INFORMATION

Ecotoxicity: No ecotoxicity data was found for the product.

Environmental Stability: No environmental information found for this product.

SECTION 13: DISPOSAL CONSIDERATIONS

Waste Disposal: Dispose of in accordance with Local, State, Federal and Provincial regulations,

SECTION 14: TRANSPORT INFORMATION

DOT Shipping Name: Not Regulated. DOT UN Number: Not Regulated.

IATA Shipping Name: Non regulated. IATA UN Number: Non regulated.

IMDG UN Number: Non regulated. IMDG Shipping Name: Non regulated.

SECTION 15: REGULATORY INFORMATION

Potassium chloride:

TSCA Inventory Status: Listed

SARA: EPCRA - 40 CFR Part 372 - (SARA Title III) Section 313 Listed Chemical.

Section 302 EHS: EPCRA (SARA Title III) Section 302 (40 CFR Part 355) Extremely Hazardous Substances (EHS) Threshold Planning Quantity (TPQ) in pounds.: 500 Lbs.

EPCRA (SARA Title III) Section 304 Extremely Hazardous Substances (EHS) Reportable Quantities (RQ) Section 304 RO:

in pounds.: 5,000 Lbs.

Canada DSL:

Canada IDL: Identified under the Canadian Hazardous Products Act Ingredient Disclosure List: 0.1%.845(502)

EC Number: 231-211-8

Sodium lactate:

TSCA Inventory Status: Listed Canada DSL: Listed EC Number: 200-772-0 <u>Calcium chloride</u>:

EC Number: 233-140-8

Sodium Chloride:

TSCA Inventory Status: Listed

Canada DSL: Listed

EC Number: 231-598-3

SECTION 16: ADDITIONAL INFORMATION

HMIS Ratings:

HMIS Health Hazard: 1
HMIS Fire Hazard: 1
HMIS Reactivity: 1
HMIS Personal Protection: X

SDS Creation Date: February 14, 2019
SDS Revision Date: February 14, 2019

Disclaimer:

The information contained herein pertains to this material. It is the responsibility of each individual party to determine for themselves the proper means of handling and using these materials based on their purpose and intended use. Fresenius-Kabi assumes no liability resulting from the use of or reliance upon the information contained in this material safety data sheet. This material safety data sheet does not constitute the guaranty or specifications of the product.

 $Copyright @ \ 1996-2018 \ Enviance. \ All \ Rights \ Reserved.$